Pharma Journalist -

Nucleai and Sirona Dx have announced a strategic partnership aimed at delivering a fully integrated spatial proteomics solution to pharmaceutical and biotechnology companies. The…
Read More...

Terremoto Biosciences has secured $108 million in a Series C financing round, strengthening its position in the race to develop next-generation targeted therapies for cancer and rare…
Read More...

Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize its investigational hepatitis B treatment,…
Read More...

Boehringer Ingelheim and Zai Lab have announced a new clinical collaboration aimed at advancing a novel dual-targeting strategy for difficult-to-treat cancers. The partnership will…
Read More...

Sana Biotechnology has announced a strategic collaboration with Mayo Clinic to accelerate the development of SC451, an investigational cell therapy aimed at transforming treatment for…
Read More...

CrossBridge Bio, Inc., a pre-clinical biotech firm specializing in next-generation antibody-drug conjugates (ADCs), has agreed to be acquired by Eli Lilly and Company in a deal valued…
Read More...

As New Approach Methodologies (NAMs) and microphysiological systems (MPS) continue to gain momentum across drug development, the imperative facing industry scientists is increasingly…
Read More...

Replimune Group has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application (BLA) seeking approval of RP1 in…
Read More...

Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies, marking…
Read More...

AbbVie has announced encouraging late-breaking results from its Phase 2 IMGN853-0420 clinical trial, showcasing the potential of mirvetuximab soravtansine-gynx in treating recurrent…
Read More...